# A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

> **NCT04196283** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 30 (actual)

## Conditions studied

- Advanced Solid Tumors Cancer

## Interventions

- **DRUG:** ABBV-368
- **DRUG:** Tilsotolimod
- **DRUG:** Nab-paclitaxel
- **DRUG:** ABBV-181

## Key facts

- **NCT ID:** NCT04196283
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-22
- **Primary completion:** 2022-10-27
- **Final completion:** 2022-10-27
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04196283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04196283, "A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04196283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*